PRO1160 for Advance Solid and Liquid Tumors (PRO1160-001)
Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
Brief Summary:
This study will test the safety, including side effects, and determine the characteristics of
a drug called PRO1160 in participants with solid tumors.
Participants will have solid tumor or liquid cancer that has spread through the body
(metastatic) or cannot be removed with surgery (unresectable).
This study will have two parts. Part A of the study will find out how much and how frequently
PRO1160 should be given to participants. Part B will use the dose and schedule found in Part
A to find out how safe PRO1160 is and if it works to treat the diseases under study.
Renal Cell Carcinoma (RCC) Drug: PRO1160 Phase 1/Phase 2 Nasopharyngeal Carcinoma (NPC)
Non-Hodgkin Lymphoma (NHL)